E

Gems from the ASCO17 Poster Hall Part 1

A look at how liver mets can negatively impact cancer immunotherapies

June 22, 2017
E

Can a vaccine make a difference in sarcoma?

What can we learn from the Immune Design data in sarcomas with their NY-ESO-1 vaccine?

June 21, 2017
E

New developments in sarcoma

What's new in the sarcoma space? Which novel approaches are worth watching out for?

June 20, 2017
E

A promising IO combo approach to watch out for

Overcoming resistance to monotherapy treatment with checkpoint blockade is crucial for success with IO combos. Here's one potential solution...

June 19, 2017
E

APHINITY – How much better and for whom?

Thought leader reactions and sentiments to the APHINITY readout in adjuvant HER2+ breast cancer

June 16, 2017
E

New IO developments in breast cancer

A look at checkpoint blockade in early stage breast cancer - encouraging or not?

June 14, 2017
E

Going beyond PARP monotherapies

A look at PARP as it journeys from 1999 to 2017 culminating in a plenary presentation at ASCO

June 13, 2017
E

An in-depth look at OLYMPIAD in HER2 negative breast cancer

Olaparib is the first PARP to demonstrate a clinical benefit in HER2- breast cancer - what do KOLs really think?

June 12, 2017
E

Trends, Highlights and Lowlights from ASCO 2017

Beyond the incremental improvements seen in clinical trials, what are the new trends emerging from ASCO 2017 that will impact oncology R&D?

June 6, 2017
E

ASCO17 Preview A Strategic Look at Emerging Themes

Chicago! Right now many people are overwhelmed not just with the sheer number of ASCO abstracts to…

May 31, 2017
E

ASCO17 Top 10 Abstracts

Our Top 10 #ASCO17 abstracts to watch out for

May 26, 2017
E
Chicago River

ASCO 2017 CAR T Cell Therapy Preview

Some intriguing surprises in the CAR T cell therapy abstracts this year...

May 24, 2017
E
ASCO 2014 Chicago Contemplation

An up and coming area in early oncology R&D

A look at an up and coming niche in cancer research that may turn out to be useful in conjunction with checkpoint blockade

May 22, 2017
E

5 key abstracts to consider from ASCO 2017

A look at 5 key abstracts that tickled my fancy from #ASCO17; Warning - not all are positive!

May 18, 2017
E

ASCO 2017 Preview 2 – IDO1 Inhibitors

Update on #ASCO17 data for IDO1 inhibitors in various cancers

May 17, 2017
E

Things we need to think about ahead of ASCO17

A fireside chat with a leading KOL involved in cancer research on resistance.

May 16, 2017
E

Going Beyond PARP in DNA Damage Repair

A look a one company's approach to DDR and potential combination opportunities in this niche

May 9, 2017